CURRENCYFAIR
More than a third of British expats (34 percent) are already actively seeking a formal farewell to their home country due Brexit, and a further 5 percent will seek citizenship for themselves and/or their family in case of a hard Brexit, according to a survey commissioned by international money transfer service CurrencyFair.
The survey, concluding in May, compared British expats’ preferred Brexit outcomes and plans for Brexit with the views of British citizens residing at home. Expats living in EU countries that are expected to be most significantly impacted by Brexit were surveyed, including Germany, France, the Netherlands and Ireland.
Voting with their passports
Over half of the British citizens living outside of the UK surveyed are worried about their citizenship rights as an expat (53 percent), and half (50 percent) are concerned about their citizenship rights in commonwealth countries due to Brexit, which may be a trigger for the rush to seek a citizenship berth outside of their birth country.
"Expats tend to be at the leading edge of the intersection between personal finance and current events, and their behaviour is a barometer for bigger trends and changes,” said Paul Byrne, CEO of CurrencyFair. “Our research indicates that Brexit may be forcing the hand of expats to seek citizenship they might not otherwise seek, as they search for viable options in the event of a hard Brexit and any negative economic consequences.”
Bracing for a recession
In addition to alternative citizenship, a quarter of British expats surveyed say they plan to brace for a recession in the event of a hard Brexit, and plan to liquidate UK assets (17 percent) or transfer money abroad (13 percent) if the UK crashes out of the EU without a deal. A third of expats noted that when choosing a provider to transfer money to and from the UK, transparency about fees charged ranks first as the most important aspect, tied with security and trust in service provider.
“People are hearing our message that paying marked up exchange rates and hidden fees for currency exchange isn’t sustainable for expats from a personal finance perspective,” Byrne said
Overall, expats are more worried than UK residents about the uncertainty surrounding the UK’s departure from the EU, from the amount of debt they currently have (42 percent for expats versus 20 percent for UK residents), to the impact of Brexit on their retirement (52 percent expats versus 34 percent in the UK), and their ability to buy the things they want (52 percent expats versus 41 percent in the UK).
This worry is translating into immediate action for many expats who revealed they are already focusing on paying off any unsecured debt (16 percent versus 12 percent in the UK), moving investments to lower risk funds (14 percent versus five percent in the UK), and changing retirement plans (14 percent versus two percent in the UK).
The survey revealed that UK citizens residing at home have a certain confidence when it comes to their own finances. While 54 percent are concerned that the UK economic situation will worsen over the next 12 months, the same percentage believe their individual economic situation will either stay the same or improve. Additionally, the majority of UK residents (54 percent) indicate they plan to do nothing if there is a no-deal Brexit beyond bracing for a recession (42 percent).
“The survey suggests that expats and UK citizens residing at home have contrasting views when it comes to how they anticipate Brexit will affect their lives. It’s clear that when it comes to Brexit, where one stands on the issues depends on where one sits in the world,” said Byrne.
The Irish question
In the Brexit blame game, the Irish government gets off scot-free. Only four percent of British expats surveyed hold the Irish government responsible, despite assertions in some media quarters that the Irish government has ‘overplayed its hand’ on Brexit. A full twenty-seven percent of British expats in Ireland, however, blame the mainstream media or ‘fake news’ for the state of Brexit negotiations. Interestingly, British expats living in Ireland are significantly more likely than others to blame the British public for the current state of affairs. Twenty-seven percent say the British public is at fault, compared to just 16 percent of expats in other countries that blame their fellow countrymen.
Leadership vacuum
The likes of British prime ministers Theresa May and David Cameron, however, take the lion’s share of blame for the current state of Brexit negotiations. Both UK citizens residing at home and expats struggled to suggest an appropriate alternative, with only one in 10 expats choosing Michael Gove, and one in 10 UK citizens residing at home choosing Boris Johnson. When asked which notable person - living or dead - would have Brexit sorted by now if they were in charge, 32 percent of UK nationals said former prime minister Margaret Thatcher and 24 percent said they felt former prime minister Winston Churchill would get the job done. Expats living in France and Germany felt leaders in their adoptive countries, president Emmanuel Macron and chancellor Angela Merkel, respectively, would do a better job handling Brexit. Kylie Minogue ranked second in both Germany and The Netherlands with 15 percent and 18 percent respectively choosing the singer. Twelve percent of expats surveyed in the Netherlands chose Meghan, Duchess of Sussex, formerly known as Meghan Markle.
All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 664 adults. Fieldwork was undertaken between 18th April - 2nd May 2019. The survey was carried out online. The figures have been weighted and are representative of all GB adults (aged 18+).
-30-
CurrencyFair is an international money transfer platform focused on providing the best available exchange rates and experience for customers who need to send money and make payments overseas. CurrencyFair’s 150,000 strong user-community have traded more than €8 billion and saved more than €205 million using the service. Our unique peer-to-peer model and secure, state-of-the-art technology, raises the industry standard in designing technology-led foreign currency services for web, IOS and Android use. The company has offices in Ireland, Singapore, Hong Kong and Australia, and announced plans to expand further across Asia in 2019 after acquiring Convoy Payments (Hong Kong) in December 2018.
…
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005288/en/
Contact:
Killeen Kelly killeenkelly@currencyfair.com +353 87 380 6879
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
